Scientists Map 31 Semaglutide Metabolites Across Species Using New Lab Method | Research

The takeaway

A new mass spectrometry method identified 31 semaglutide metabolites in liver fractions from five species and rat plasma, establishing a screening framework for peptide drug development.

31 metabolites
Identified across 5 species using a novel UHPLC-HRMS method for semaglutide

What the researchers found

31 semaglutide metabolites identified across five species, with peptide backbone hydrolysis as the primary metabolic pathway and a diagnostic m/z 469 fragment enabling efficient screening.

Why it matters

Understanding how peptide drugs are metabolized is critical for safety and efficacy assessment. This method fills a gap in peptide drug development by providing a reliable in vitro screening model.

How the study worked

In vitro liver S9 incubation across 5 species plus in vivo rat plasma analysis using UHPLC-HRMS with data-dependent acquisition.

What this study cannot tell us

Liver S9 fractions do not capture all in vivo metabolic pathways (e.g., kidney metabolism, gut microbiome). The rat in vivo dose (10 mg/kg) far exceeds clinical human doses.

How to read the evidence

Rigorous analytical chemistry study establishing a methodological framework; not a clinical efficacy study.

When this study was published

Published in 2026.

The bigger picture

As peptide therapeutics proliferate (GLP-1 drugs, amylin analogs, etc.), robust metabolite screening methods become essential for the entire drug class, not just semaglutide.

Questions still open

Do any of the 31 metabolites have pharmacological activity or toxicity?
Can this method be adapted to screen metabolites of other GLP-1 drugs like tirzepatide?
How well do in vitro S9 metabolite profiles predict human in vivo metabolism?

Common questions

Why does it matter how semaglutide is broken down?

Knowing a drug metabolites helps researchers predict potential drug interactions, identify possible toxic byproducts, and understand why the drug lasts as long as it does in the body.

Does this affect how patients take semaglutide?

Not directly. This is a laboratory methods study for drug developers. It does not change clinical dosing or safety recommendations for patients currently taking semaglutide.

Read the original research

Metabolite Profiling and Identification of Semaglutide in Liver S9 Across Species and Rat Plasma.

Biomedical chromatography : BMC, 40(4), e70415

View on PubMed ↗Publisher’s paper ↗

Citation

Cong, Yawen; Tang, Chongzhuang; Li, Zhiqiang; Gao, Yang; Chen, Lijuan; Xu, Haibo; Diao, Xingxing. (2026). Metabolite Profiling and Identification of Semaglutide in Liver S9 Across Species and Rat Plasma.. Biomedical chromatography : BMC, 40(4), e70415. https://doi.org/10.1002/bmc.70415